Details for Patent: 6,143,327
✉ Email this page to a colleague
Title: | Delayed release coated tablet of bupropion hydrochloride |
Abstract: | The invention provides a delayed release coated tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a first coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer; and (iii) a second coating consisting essentially of a methacrylic polymer and a plasticizer therefor. |
Inventor(s): | Seth; Pawan (Irvine, CA) |
Assignee: | Pharma Pass LLC (Irvine, CA) |
Filing Date: | Dec 13, 1999 |
Application Number: | 09/459,459 |
Claims: | 1. A delayed release coated tablet comprising: (i) a core comprising bupropion hydrochloride and conventional excipients, free of stabilizer; and (ii) a first coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer; and (iii) a second coating consisting essentially of a methacrylic polymer and a plasticizer therefor; exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released. 2. The tablet of claim 1, where the water-insoluble, water-permeable film-forming polymer is ethylcellulose. 3. The tablet of claim 1, where the water-soluble polymer is polyvinylpyrrolidone. 4. The tablet of claim 1, where the plasticizer is 25 polyethyleneglycol. 5. The tablet of claim 1, where the methacrylic polymer is a methacrylic acid co-polymer. 6. The tablet of claim 1, where the plasticizer for the methacrylic polymer is triethyl citrate, polyethyleneglycol or a mixture thereof. 7. The tablet of claim 1, where in the first coating, the 35 water-insoluble, water-permeable film-forming polymer is ethylcellulose, the water-soluble polymer is polyvinylpyrrolidone, the plasticizer is polyethyleneglycol and where in the second coating, the methacrylic polymer is a methacrylic acid co-polymer, the plasticizer is triethyl citrate, polyethyleneglycol or a mixture thereof. 8. The tablet of claim 1, where the core comprises a binder and a lubricant. 9. The tablet of claim 8, where the core comprises polyvinyl alcohol and glyceryl behenate. 10. The tablet of claim 1, comprising from 50 to 400 mg bupropion hydrochloride. 11. The tablet of claim 7, comprising from 50 to 400 mg bupropion hydrochloride. 12. The tablet of claim 9, comprising from 50 to 400 mg bupropion hydrochloride. 13. A delayed release coated tablet comprising: (i) a core consisting essentially of bupropion hydrochloride, polyvinylalcohol and glyceryl behenate; and (ii) a first coating consisting essentially of ethylcellulose, polyvinylpyrrolidone and polyethyleneglycol; and (iii) a second coating consisting essentially of methacrylic acid co-polymer, triethyl citrate, polyethyleneglycol and optionally silicon dioxide; exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released. 14. The tablet of claim 13, comprising from 50 to 400 mg bupropion hydrochloride. 15. A bupropion hydrochloride delayed release coated tablet free of stabilizer and free of pore-forming agent, exhibiting a dissolution profile such that after 2 hours, from 0 up to 30% of the bupropion hydrochloride is released, after 4 hours, from 3 to 22% of the bupropion hydrochloride is released, after 6 hours, from 15 to 38% of the bupropion hydrochloride is released, after 8 hours, more than 40% of the bupropion hydrochloride is released. 16. The tablet of claim 15, comprising from 50 to 400 mg bupropion hydrochloride. 17. A tablet comprising the delayed release coated tablet of claim 1, coated with a bupropion hydrochloride immediate release coating. 18. A tablet comprising the delayed release coated tablet of claim 13, coated with a bupropion hydrochloride immediate release coating. 19. A tablet comprising the delayed release coated tablet of claim 15, coated with a bupropion hydrochloride immediate release coating. |